Nevada: Support Schedule I for All Kratom

Nevada's original whole-kratom Schedule I proposal (R105-26) was withdrawn on June 29, 2026 — but the issue is not over. The Board is expected to return the proposal to a workshop for additional public comment on September 3, 2026.

SUBMIT COMMENT BOARD CONTACTS

Current Status

R105-26: WITHDRAWN
June 29, 2026
Kratom Schedule I status: NOT ADOPTED
Next anticipated action: Additional Board workshop / public comment
September 3, 2026

This page will be updated when the Nevada State Board of Pharmacy publishes the official September agenda, workshop notice and any replacement regulatory language.

The Nevada State Board of Pharmacy previously proposed one of the broadest kratom scheduling rules in the country. LCB File R105-26 would have placed whole kratom — not merely concentrated 7-OH products — into Schedule I. That regulatory file was withdrawn by the Board on June 29, 2026.

The withdrawal means R105-26 was not adopted and is no longer an active proposed regulation. Kratom has not been placed into Schedule I under R105-26. However, Board tracking information indicates that the issue is expected to return for additional public comment on September 3, 2026.

Until the Board publishes the new workshop notice, agenda and proposed language, supporters should ask Nevada to preserve the comprehensive approach contained in R105-26.

What R105-26 Actually Proposed

The withdrawn regulation went considerably further than scheduling three isolated alkaloids. R105-26 proposed Schedule I control of any material, compound, mixture or preparation containing any quantity of kratom, including natural, synthetic and semisynthetic substances associated with Mitragyna speciosa.

The proposed language specifically included:

In other words, R105-26 did not create a “natural leaf” exemption. That distinction matters.

Where It Is in the Pipeline

📜
COMPLETED
April 16, 2026 – Board workshop / public consideration. The Nevada State Board of Pharmacy considered the proposed addition of kratom substances to Schedule I.
📄
COMPLETED
May 5, 2026 – R105-26 posted. The Legislative Counsel Bureau published the initial draft of R105-26.
⚠
WITHDRAWN
June 29, 2026 – R105-26 withdrawn. The Nevada Register officially records R105-26 as “Withdrawn by agency.” This ended that particular regulatory file. It was not adopted.
⚡
UPCOMING
September 3, 2026 – Additional public input anticipated. Board tracking information indicates the kratom proposal is being returned to a workshop to solicit additional public comments.
Important: Until the Board publishes the September agenda, workshop notice and any revised regulatory language, the precise scope of the next proposal should not be assumed.

What Supporters Should Ask Nevada to Do

The question now isn't whether to support the withdrawn R105-26 file as though it were still pending. The question is what Nevada puts into its replacement proposal.

We are asking the Nevada State Board of Pharmacy to retain the comprehensive approach reflected in R105-26 and recommend Schedule I control that includes:

Do not reduce the proposal to commercially concentrated 7-OH.
Do not create a “natural leaf” loophole.
Do not create an arbitrary concentration threshold that leaves psychoactive mitragynine-containing products on convenience-store shelves.

Why Whole Kratom Matters

The current policy debate increasingly attempts to divide the market into supposedly acceptable “natural kratom” and unacceptable concentrated 7-OH products. That distinction does not resolve the underlying regulatory question.

Mitragynine is the principal alkaloid in conventional kratom and is pharmacologically active. Mitragynine is also metabolized in humans to 7-hydroxymitragynine.

Kratom-associated poison-center cases, dependence, withdrawal, adverse events and deaths were documented years before the recent commercial market for concentrated 7-OH products emerged.

If Nevada concludes that kratom satisfies its statutory requirements for Schedule I, the regulation should address the substance comprehensively rather than simply moving the regulatory line from one kratom alkaloid to another.

Submit Public Comment

Send your comment to the Board's official public comment inbox. It will be logged into the regulatory record.

Primary – Public Comment Inbox:
teambc@pharmacy.nv.gov

This is the official channel for public comments. Copy pharmacy@pharmacy.nv.gov for broader visibility.

Suggested subject:
September 3 Kratom Workshop — Support Schedule I for All Kratom
Important note on the withdrawn status:
Because R105-26 has been withdrawn, supporters should not describe their submission as a comment on an active R105-26 proceeding. Instead, identify R105-26 as the previous proposal and ask that its whole-kratom scope be preserved in any successor rulemaking.

Suggested Comment

Subject: September 3 Kratom Workshop — Support Schedule I for All Kratom

To the Nevada State Board of Pharmacy:

I support Schedule I control of kratom and urge the Board to preserve the comprehensive scope reflected in former LCB File R105-26.

I understand that R105-26 was withdrawn on June 29, 2026 and therefore was not adopted. My comment concerns the Board's continued consideration of kratom and any successor proposal.

The replacement proposal should not be limited to commercially concentrated or synthetic 7-hydroxymitragynine.

I urge the Board to consider Schedule I control encompassing natural Mitragyna speciosa material and preparations, mitragynine, 7-hydroxymitragynine, mitragynine pseudoindoxyl, and appropriate related derivatives, analogs and isomers.

Please evaluate the complete kratom pharmacology and public-health record under Nevada's statutory scheduling criteria, including abuse potential, pharmacological effects, current scientific knowledge, patterns and significance of abuse, risk to public health, dependence liability, accepted medical use and accepted safety for use under medical supervision.

Please include this submission in the record associated with the Board's upcoming consideration of kratom.

Respectfully,
[Name]
[City, State]
EMAIL YOUR COMMENT (copy & paste the letter)

Click the button above to open your email client. Then copy the letter from the box above, paste it into the email body, add your name and city, and send.

Who to Contact – Board of Pharmacy

This is rulemaking, not legislation. The Board of Pharmacy makes the decision. Legislators are not involved at this stage. Focus your pressure here:

Primary (Public Comment – Official Record)
teambc@pharmacy.nv.gov
Copy: pharmacy@pharmacy.nv.gov
Secondary (General Board Inbox)
pharmacy@pharmacy.nv.gov
Timing is everything: The next key event is the September 3, 2026 Board workshop. Comments submitted in advance help shape the scope of the replacement proposal.

Preserve the Comprehensive Approach

R105-26 may have been withdrawn, but the fight for a whole-kratom Schedule I is not over.
Send your comment now and urge Nevada to close the loopholes.

SUBMIT OFFICIAL COMMENT NOW VIEW FULL TEMPLATE
← Anti‑Kratom Association Home | Evidence | Industry Hub